Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 8/20 | 0.62 |
| ▸ | RAB9A | P51151 | 8/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.59 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.59 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.59 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.59 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8317450 | 0.89 | NPC1 (0.65) | CSF1RKMT2AMEN1KCNK3L3MBTL1 | |
| SCHEMBL2495198 | 0.86 | KCNK3 (0.67) | CSF1RKMT2AMEN1KCNK3NPC1 | |
| SCHEMBL4250694 | 0.86 | NPC1 (0.71) | CSF1RKMT2AMEN1KCNK3L3MBTL1 | |
| SCHEMBL19976062 | 0.86 | NPC1 (0.73) | KMT2AMEN1KCNK3NPC1RAB9A | |
| SCHEMBL2493233 | 0.84 | KCNK3 (0.68) | CSF1RKMT2AMEN1KCNK3L3MBTL1 | |
| SCHEMBL2497820 | 0.83 | CSF1R (0.70) | CSF1RKMT2AMEN1KCNK3RAB9A | |
| SCHEMBL13187385 | 0.82 | KMT2A (0.74) | KMT2AMEN1KCNK3L3MBTL1NPC1 | |
| SCHEMBL3934183 | 0.81 | CSF1R (1.00) | CSF1RL3MBTL1NPC1RAB9AKCNQ3 | |
| SCHEMBL6802691 | 0.80 | KMT2A (0.78) | KMT2AMEN1KCNK3L3MBTL1NPC1 | |
| SCHEMBL1811680 | 0.80 | L3MBTL1 (0.82) | KMT2AMEN1KCNK3L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2008008234-A1 | 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008234-A1 | 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | KDR, FLT4, FLT1 | CSF1R 575/4885KMT2A 1762/4885MEN1 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.